论文部分内容阅读
[目的]探讨CEA、CYFRA21-1、CA125联合检测在肺癌诊断中的价值。[方法]采用电化学发光法检测肺部疾病患者血清中CEA、CYFRA21-1、CA125浓度水平。[结果]肺癌组血清CEA、CYFRA21-1、CA125水平均明显高于肺部良性病变组及正常对照组,经统计学分析差异显著。其中CEA、CA125以肺腺癌中最高,阳性率分别78.13%、65.63%;CYFRA21-1以肺鳞癌中最高,阳性率达51.9%。肿瘤患者单独检测以上肿瘤标志物阳性率较低(CEA28.00%,CYFRA21-1 36.80%,CA125 30.40%。而联合检测以上标志物阳性率则大大提高,肺癌的检测阳性率可达70.41%,肺鳞癌达64.56%,腺癌达87.50%,小细胞癌达63.64%。[结论]临床上适当选用多项血清肿瘤标志物联合检测有利于肺癌的早期诊断与鉴别诊断。
[Objective] To investigate the value of combined detection of CEA, CYFRA21-1 and CA125 in the diagnosis of lung cancer. [Method] The concentrations of CEA, CYFRA21-1 and CA125 in serum of patients with pulmonary diseases were detected by electrochemiluminescence. [Results] The levels of serum CEA, CYFRA21-1 and CA125 in lung cancer group were significantly higher than those in benign lung disease group and normal control group, and the difference was statistically significant. Among them, CEA and CA125 were the highest in lung adenocarcinoma, the positive rates were 78.13% and 65.63% respectively; CYFRA21-1 was the highest in lung squamous cell carcinoma with a positive rate of 51.9%. The positive rate of tumor markers detected by tumor patients was lower (CEA28.00%, CYFRA21-1 36.80%, CA125 30.40%), while the positive rate of the above markers was greatly increased, with the detection rate of lung cancer reaching 70.41% 64.56% in lung squamous cell carcinoma, 87.50% in adenocarcinoma, and 63.64% in small cell carcinoma. [Conclusions] The appropriate combination of multiple serum tumor markers in clinic is helpful for the early diagnosis and differential diagnosis of lung cancer.